Terms: = Lung cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
312 results:
1. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
[TBL] [Abstract] [Full Text] [Related]
2. cancer trend and radiotherapy utilization at a tertiary academic hospital in Malaysia.
Gan DEH; Bustam AZ
J Cancer Res Ther; 2024 Jan; 20(1):358-362. PubMed ID: 38554346
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract] [Full Text] [Related]
4. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.
Zhang Q; Li Y; Zhang Y; Deng Z; Ding Y
World J Surg Oncol; 2024 Feb; 22(1):50. PubMed ID: 38336701
[TBL] [Abstract] [Full Text] [Related]
5. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
[TBL] [Abstract] [Full Text] [Related]
6. Non-coplanar lung SABR treatments delivered with a gantry-mounted x-ray tube.
O'Connell J; Weil MD; Bazalova-Carter M
Phys Med Biol; 2024 Jan; 69(2):. PubMed ID: 38035372
[No Abstract] [Full Text] [Related]
7. Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell lung cancer Cell Line H1975.
Tong X; Zhang R; Sun R; Yang W; Sun J; Chen J; Li F
Anticancer Res; 2023 Dec; 43(12):5459-5474. PubMed ID: 38030186
[TBL] [Abstract] [Full Text] [Related]
8. Enhancing Symptom Screening and Patient Education Among Patients with Metastatic lung cancer: a Qualitative Analysis.
Safavi AH; Bryson E; Delibasic V; Tjong MC; Hallet J; Mahar A; Davis LE; Wright FC; Parmar A; Coburn NG; Louie AV
J Cancer Educ; 2024 Feb; 39(1):86-95. PubMed ID: 37962792
[TBL] [Abstract] [Full Text] [Related]
9. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant lung cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract] [Full Text] [Related]
10. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell lung cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Paz-Ares L; Garassino MC; Chen Y; Reinmuth N; Hotta K; Poltoratskiy A; Trukhin D; Hochmair MJ; Özgüroğlu M; Ji JH; Statsenko G; Conev N; Bondarenko I; Havel L; Losonczy G; Xie M; Lai Z; Godin-Heymann N; Mann H; Jiang H; Shrestha Y; Goldman JW
Clin Cancer Res; 2024 Feb; 30(4):824-835. PubMed ID: 37801329
[TBL] [Abstract] [Full Text] [Related]
11. Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.
Del Giglio A; da Costa Aguiar Alves B; Murad AM; Fonseca FLA
J Med Case Rep; 2023 Sep; 17(1):407. PubMed ID: 37743480
[TBL] [Abstract] [Full Text] [Related]
12. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Leary A; Oaknin A; Trigo JM; Moreno V; Delord JP; Boni V; Braña I; Fernández C; Kahatt C; Nieto A; Cullell-Young M; Zeaiter A; Subbiah V
Eur J Cancer; 2023 Oct; 192():113259. PubMed ID: 37634282
[TBL] [Abstract] [Full Text] [Related]
13. Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.
Vitlarov N; Burtscher E; Pfeiffenberger E; Wahl A; Hodja V; Jasarevic Z; Kashofer K; Offner FA
Virchows Arch; 2023 Dec; 483(6):873-878. PubMed ID: 37428268
[TBL] [Abstract] [Full Text] [Related]
14. Bioinformatics analysis and in vivo validation study of Ophiocordyceps sinensis (Berk.)G.H.Sungetal against lung adenocarcinoma.
Zhang X; Wang M; Liang X; Wang J; Zhang M; Li C; Wei L; Bi H
J Ethnopharmacol; 2023 Dec; 317():116739. PubMed ID: 37315647
[TBL] [Abstract] [Full Text] [Related]
15. Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.
Sung C; An J; Lee S; Park J; Lee KS; Kim IH; Han JY; Park YH; Kim JH; Kang EJ; Hong MH; Kim TY; Lee JC; Lee JL; Yoon S; Choi CM; Lee DH; Yoo C; Kim SW; Jeong JH; Seo S; Kim SY; Kong SY; Choi JK; Park SR
Nat Cancer; 2023 Jun; 4(6):844-859. PubMed ID: 37308678
[TBL] [Abstract] [Full Text] [Related]
16. New Markers for Management of Mesothelioma.
Nash A; Firth Née Phan T; Creaney J
Semin Respir Crit Care Med; 2023 Aug; 44(4):491-501. PubMed ID: 37253383
[TBL] [Abstract] [Full Text] [Related]
17. Neovascular glaucoma caused by small-cell lung cancer iris metastasis: A case presentation.
Rallo-López AJ; Orts-Llácer J; Cauto-Picazo C; Peñarrocha-Oltra S; Martínez-Costa R
Arch Soc Esp Oftalmol (Engl Ed); 2023 Aug; 98(8):482-485. PubMed ID: 37247662
[TBL] [Abstract] [Full Text] [Related]
18. [A Case of Rectal Neuroendocrine Carcinoma with iris Metastasis].
Matsuo Y; Ichikawa Y; Sawada G; Takada A; Kim HM; Murakami M; Fukunaga H; Shirai S; Kondou S; Kimura H; Morita S
Gan To Kagaku Ryoho; 2023 May; 50(5):647-649. PubMed ID: 37218331
[TBL] [Abstract] [Full Text] [Related]
19. Mutations and expressions of breast cancer 1/2 in lung cancer.
Yan B; Xie B; Huang M; Guo J; Sun J; Chen J; Tao Y; Xiao D
Thorac Cancer; 2023 Jun; 14(18):1753-1763. PubMed ID: 37160413
[TBL] [Abstract] [Full Text] [Related]
20. Diospyros malabarica fruit preparation mediates immunotherapeutic modulation and epigenetic regulation to evoke protection against non-small cell lung cancer (NSCLC).
Bhootra S; Jill N; Rajak R; Shanmugam G; Rakshit S; Kannanthodi S; Thakkar V; George M; Sarkar K
J Ethnopharmacol; 2023 Oct; 314():116525. PubMed ID: 37149067
[TBL] [Abstract] [Full Text] [Related]
[Next]
